Seleneinsatz in der Onkologie

Zusammenfassung

Selen ist ein essenzielles Spurenelement mit onkologischem Potenzial. Bei der krebspräventiven Wirkung besteht eine Abhängigkeit zum Selenspiegel im Blut. Der krebstherapeutische Effekt von Selen konnte inzwischen in einigen Studien im Rahmen der Therapie verschiedener Krebsarten gezeigt werden.

Selen - Selensupplementation - Onkologie - Prävention - Therapie

Literatur

• 1 Asfour I A, Shazly S E, Fayek M H et al. Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients.  Biol Trace Elem Res. 2006;  110 19-32
• 2 Asfour I A, Fayek M H, Raouf S et al. The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival.  Biol Trace Elem Res. 2007;  120 1-10
• 3 Asfour I A, El-Tehewi M M, Ahmed M H et al. High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-Hodgkin's lymphoma.  Biol Trace Elem Res. 2009;  127 200-210
• 4 Beck M A, Nelson H K, Shi Q et al. Selenium deficiency increases the pathology of an influenza virus infection.  FASEB J. 2001;  15 1481-1483
• 5 Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults.  Arch Intern Med. 2008;  168 404-410
• 6 Blot W J, Li J Y, Taylor P R et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease specific mortality in the general population.  J Natl Cancer Inst. 1993;  85 1483-1489
• 7 Brooks J D, Metter E J, Chan D W et al. Plasma selenium level before diagnosis and the risk of prostate cancer development.  J Urolog. 2001;  166 2034-2038
• 8 Büntzel J, Micke O, Mücke R et al. Amifostine and selenium during simultaneous radiochemotherapy in head and neck cancer – redox data.  Trace Elem Electrolytes. 2005;  22 211-215
• 9 Büntzel J, Glatzel M, Kisters K et al. Selenium as a radioprotector in head and neck cancer patients – first clinical results.  Trace Elem Electrolytes. 2006;  23 178-180
• 10 Büntzel J, Micke O, Glatzel M et al. Evaluation of the effect of selenium on radiation-induced toxicities in head neck cancer.  J Clin Oncol. 2009;  27 (No 15 S) abstr. e20698
• 11 Clark L C, Combs G F, Turnbull B W et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin.  J Am Med Assoc. 1996;  276 1957-1963
• 12 Duffield-Lillico A J, Dalkin B L, Reid M E et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial.  BJU Int. 2003;  91 608-612
• 13 Fischer J L, Mihelc E M, Pollok K E, Smith M L. Chemotherapeutic selectivity conferred by selenium: a role for p 53-dependent DNA repair.  Mol Cancer Ther. 2007;  6 355-361
• 14 Fraunholz I, Jüling-Pohlit L, Böttcher H. Influence of selenium on acute mucositis in radiochemotherapy of head and neck tumors.  Trace Elem Electrolytes. 2001;  18 98-99
• 15 Gudkov A V. Converting p 53 from a killer to a healer.  Nature Medicine. 2002;  8 1196-1198
• 16 Hatfield D L, Gladyshev V N. The outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology.  Mol Interv. 2009;  1 18-21
• 17 Hu Y J, Chen Y, Zhang Y Q et al. The protective role of selenium on the toxicity of cisplatinum-contained chemotherapy regimen in cancer patients.  Biol Trace Elem Res. 1997;  56 331-341
• 18 Karp D D, Lee S J, Shaw Wright G L. A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium supplementation in resected stage I non-small cell lung cancer.  J Clin Oncol. 2010;  28 abstr CRA7004
• 19 Kellen E, Zeegers M, Buntinx F. Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer.  Int J Urol. 2006;  13 1180-1184
• 20 Knekt P, Aromaa A, Mantela J. Serum selenium and subsequent risk of cancer among Finnish men and woman.  J Natl Cancer Inst. 1990;  82 864-868
• 21 Last K W, Cornelius V, Delves T et al. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-hodgkin's lymphoma.  J Clin Oncol. 2003;  21 2335-2341
• 22 Last K, Maharaj L, Perry J et al. The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours.  Ann Oncol. 2006;  17 773-779
• 23 Lippmann S M, Klein E A, Goodman P J et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT).  JAMA. 2009;  301 39-51
• 24 Micke O, Bruns F, Glatzel M et al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology.  EUJIM. 2009;  1 22-30
• 25 Mücke R, Schomburg L, Glatzel M et al. Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology.  Int J Radiation Oncology Biol Phys. 2010;  70 828-835
• 26 Papp L V, Lu J, Holmgren A, Khanna K K. From selenium to selenoproteins: synthesis, identity, and their role in human health.  Antioxid Redox Signal. 2007;  9 775-806
• 27 Rayman M P. The importance of selenium to human health.  Lancet. 2000;  356 233-241
• 28 Schomburg L, Koehrle J. Selenium: benefits and risks.  MMW Fortschr Med. 2007;  149 34-36
• 29 Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy.  Gynecol Oncol. 2004;  93 320-327
• 30 Vunta H, Davis F, Palempalli U D et al. The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta12, 14-prostaglandin J2 in macrophages.  J Biol Chem. 2007;  282 17964-17973
• 31 Weijl N I, Elsendoorn T J, Lentjes E G et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study.  Eur J Cancer. 2004;  40 1713-1723
• 32 Yu S Y, Mao B L, Xiao P et al. Intervention trial with selenium for the prevention of lung cancer among tin miners in Yunnan, China. A pilot study.  Biol Trace Elem Res. 1990;  24 105-108
• 33 Yu S Y, Zhu Y J, Li W G et al. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China.  Biol Trace Elem Res. 1991;  29 289-294

Dr. Ralph Mücke

Strahlentherapeutische Klinik
Klinikum Lippe GmbH

Rintelner Straße 85

32657 Lemgo

Email: [e-mail]

Dr. Ralph Mücke studierte in Rostock Medizin. Nachdem er seinen Facharzt für Strahlentherapie absolviert hatte, war er zunächst am Klinikum Weiden in der Oberpfalz als Oberarzt tätig. Danach praktizierte er in der Gemeinschaftspraxis für Radiologie und Strahlentherapie am St. Josef-Hospital in Wiesbaden, seit 2009 arbeitet er als Leitender Arzt der Strahlentherapeutischen Klinik am Klinikum Lippe GmbH.